sEH/HDAC6-IN-1 (compound M9) serves as a selective, orally active dual inhibitor targeting both sEH and HDAC6. It demonstrates IC50 values of 2 nM for human sEH, 0.72 nM for murine sEH, and 5 nM for HDAC6. Notably, sEH/HDAC6-IN-1 exhibits analgesic and anti-inflammatory effects [1].

HDAC11:0.3142 μM, HDAC1:0.2731 μM, HDAC3:0.49 μM, HDAC6:5 nM, murine sEH:0.72 nM, human sEH:2 nM

sEH/HDAC6-IN-1 inhibits the growth of THP-1 cells with an IC₅₀ value of 3.2 μM at a concentration of 1-2 μM over 24 hours [1]. At 100 μM, it exhibits stability in human, rat, and mouse liver microsomes, with half-lives of 4.07, 1.76, and 1.39 hours, respectively [1]. In a cell viability assay, this compound increased the levels of acetylated α-tubulin [1]. Cell Line: THP-1.